Autolus is actively investigating the safety and efficacy of multiple investigational therapy product candidates intended to treat serious diseases in ongoing clinical studies.
Information on our active clinical studies can be found on www.clinicaltrials.gov.
A physician may want to obtain information or request access to an Autolus investigational therapy product candidate for their patient who is not eligible for one of our ongoing clinical studies.
Autolus is not currently making its investigational therapy product candidates available on an expanded access basis. In the event Autolus is able to consider making one or more of its investigational therapy product candidates available through an expanded access program, on a case by case basis, requests for expanded access can be made to Autolus at email@example.com.
The request for access to the Autolus investigational therapy product candidate must be made by the patient’s treating physician. It is anticipated that Autolus will acknowledge receipt of any expanded access questions or requests within seven business days of receipt. These requests will be evaluated in accordance with applicable laws and regulations. Considerations for these requests are considered on a case-by-case basis in a fair and equitable manner.
This policy shall not serve as a guarantee of access to any specific investigational therapy by any individual patient. Autolus can revise this policy at any time.